For the quarter ending 2025-09-30, IMUX made $26,412K in revenue. -$25,579K in net income. Net profit margin of -96.85%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 20,012 | 21,369 | ||
| General and administrative | 5,981 | 5,714 | ||
| Total operating expenses | 25,993 | 27,083 | ||
| Loss from operations | -25,993 | -27,083 | ||
| Interest income | 419 | 241 | ||
| Change in fair value of the tranche rights | 0 | 0 | ||
| Other income (expense), net | -5 | 22 | ||
| Total other income (expense) | 414 | 263 | ||
| Net loss | -25,579 | -26,820 | ||
| Net loss per share, basic (in usd per share) | -0.13 | -0.2 | ||
| Net loss per share, diluted (in usd per share) | -0.13 | -0.2 | ||
| Weighted-average common shares outstanding, basic (in shares) | 193,897,764 | 132,175,202 | ||
| Weighted-average common shares outstanding, diluted (in shares) | 193,897,764 | 132,175,202 | ||
IMMUNIC, INC. (IMUX)
IMMUNIC, INC. (IMUX)